KMT2A and acute lymphoblastic leukemia: Comparing the 200 most effective Spectrum library compounds for the MLL-rearranged ALL cell lines with those for the BCP-ALL cell lines, revealed an overlap of 148 compounds (74%), suggesting that most of these drugs are not specifically targeting MLL-rearranged ALL (Figure 1c,d).